RAPS RAC-US Daily Practice Exam New 2023 Updated 100 Questions
Use Valid RAC-US Exam - Actual Exam Question & Answer
The RAC-US exam is designed to test an individual's knowledge and understanding of the regulations and laws that govern the development, marketing, and distribution of medical products. The exam covers a wide range of topics, including regulatory strategy, clinical trial design, quality systems, and post-marketing surveillance.
The Regulatory Affairs Certification (RAC) is a globally recognized certification program that aims to assess the knowledge and expertise of regulatory professionals in the pharmaceutical, medical device, and biotechnology industries. The RAC certification program is offered by the Regulatory Affairs Professionals Society (RAPS), which is a leading professional organization for regulatory affairs professionals. The RAC certification program is designed to demonstrate the proficiency of regulatory professionals in understanding and navigating the complex regulatory landscape in the healthcare industry.
NEW QUESTION # 10
When applying for marketing approval of a drug for a rare disease, which requirement can be waived?
- A. Pre-clinical studies
- B. Phase III clinical trials
- C. Phase I and II clinical trials
- D. Phase I clinical trials
Answer: B
NEW QUESTION # 11
Which of the following statements regarding export regulations for an approved product is CORRECT?
- A. The product must not be labeled on the outside of the shipping package that it is intended for export.
- B. The product must not be sold or offered for sale in domestic commerce.
- C. The product must not be in conflict with the laws of the country to which it is intended for export.
- D. The product must not be in accord with the specifications of the foreign purchaser.
Answer: C
NEW QUESTION # 12
Which of the following is MOST appropriate for the purpose of lot release of biologics?
- A. Quality verification
- B. Inventory control
- C. Safety assurance
- D. Efficacy confirmation
Answer: A
NEW QUESTION # 13
Company X and Company Y both have products for the treatment of rare genetic diseases.
Company X would like to acquire Company Y but does not know enough about Company Y to make an offer.
What is the MOST appropriate approach that Company X should take to acquire more information about Company Y?
- A. Enter into an agreement with Company Y to perform due diligence.
- B. Perform a thorough library search to gather detailed information on Company Y.
- C. Request the needed information from the Board of Directors of Company Y.
- D. Recruit a professional to gather confidential intelligence on Company Y.
Answer: A
NEW QUESTION # 14
As part of the regulatory strategy for companies intending to manufacture a psychotropic product, which of the following approvals should be received FIRST?
- A. Import license
- B. Product license
- C. Export license
- D. Site license
Answer: D
NEW QUESTION # 15
According to ICH, what is the MAXIMUM amount of time in calendar days that an organization has from the initial receipt of information to report serious and unexpected ADR of a marketed product to regulatory authorities?
- A. 0
- B. 1
- C. 2
- D. 3
Answer: B
NEW QUESTION # 16
According to ISO 14971, what is the FIRST step when developing a risk management plan for a medical device?
- A. Risk control
- B. Risk analysis
- C. Risk estimation
- D. Risk management
Answer: B
NEW QUESTION # 17
The requirements for document control are located in which of the following documents?
- A. ICH guidelines
- B. WHO guidelines
- C. IEC 60601
- D. ISO 13485
Answer: D
NEW QUESTION # 18
Following the introduction of a new regulation, an evaluation of the company's products by the regulatory affairs professional indicates that 60 percent do not comply with the regulation.
What should the regulatory affairs professional do FIRST to meet the new requirement?
- A. Prepare documents for the files.
- B. Contact the trade association for advice.
- C. Request a permanent waiver from the new regulation.
- D. Communicate with the relevant internal departments.
Answer: D
NEW QUESTION # 19
Company X encounters challenges in the global life cycle management of its medical devices. Which of the following Is MOST appropriate for improving product life cycle management?
- A. Identify countries where special requirements exist during the product development phase.
- B. Utilize the STED template to complete global requirements.
- C. Initiate a global submission process after all submission data are finalized.
- D. Plan regulatory approval update meetings with senior management and stakeholders.
Answer: A
NEW QUESTION # 20
A process is ultimately validated to ensure which of the following?
- A. The process meets the regulatory requirements.
- B. The process consistently meets the desired Quantity standards
- C. The process meets the quality system requirements.
- D. The process consistently produces the desired results.
Answer: D
NEW QUESTION # 21
What is the BEST approach to ensure that raw materials, services, and sub-contractors at the level of the vendors comply with GMP requirements?
- A. Document and perform audits.
- B. Request documentation from the sub-contractor.
- C. Ask the vendor to take responsibility.
- D. Request an inspection from a regulatory authority.
Answer: A
NEW QUESTION # 22
Company X acquires Company Y.
Both companies produce pharmaceuticals distributed globally. A regulatory authority requires that all labeling for Company Y's products be converted to Company X within three months. The regulatory affairs professional at
Company X concludes that it is not feasible to meet this request within the time frame.
Which is the FIRST step that the regulatory affairs professional at Company X should take to address the situation?
- A. Submit as many labeling conversion applications as possible within the time frame and request an extension for the remaining ones.
- B. Convene an urgent meeting with internal stakeholders to inform them of the regulatory authority requirement and assign responsibilities.
- C. Request additional resources from senior management in order to complete the labeling conversion within the time frame given by the regulatory authority.
- D. Develop a plan of action with tasks, timelines, and responsibilities and request an extension period from the regulatory authority.
Answer: D
NEW QUESTION # 23
Company X has a patent for an anti-inflammatory drug that will expire in one year. In order to minimize the effect of the patent expiration, which is the BEST action for the company to take?
- A. Explore litigation strategy for patent infringements on the drug.
- B. Develop a better brand-name drug in the same class.
- C. Develop a generic version of the drug.
- D. Conduct a Phase III study for a new unrelated indication of the drug.
Answer: C
NEW QUESTION # 24
During an audit of a contract manufacturing facility by a potential client, the auditor requested to be left alone in the records room. The records room contains information on all products produced by the contract manufacturer.
Which action is MOST appropriate for the regulatory affairs professional to take?
- A. Allow the auditor access to the room and records due to the current audit.
- B. Allow the auditor accompanied access to the room to retrieve the records.
- C. Deny the auditor access to the room and records due to confidentiality concerns.
- D. Deny the auditor access to the room and retrieve only the requested records.
Answer: B
NEW QUESTION # 25
......
Test Engine to Practice RAC-US Test Questions: https://pass4sure.pdfbraindumps.com/RAC-US_valid-braindumps.html